A single domain antibody against the Cys- and His-rich domain of PCSK9 and evolocumab exhibit different inhibition mechanisms in humanized PCSK9 mice

Generation and Characterization of a Novel Small Biologic Alternative to Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Antibodies, DS-9001a, Albumin Binding Domain–Fused Anticalin Protein

(2018) Yusuke Masuda et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Cholesterol-lowering drugs: science and marketing

(2017) Livio Garattini et al.   JOURNAL OF THE ROYAL SOCIETY OF MEDICINE

Estimated burden of cardiovascular disease and value-based price range for evolocumab in a high-risk, secondary-prevention population in the US payer context

(2017) Peter P. Toth et al.   JOURNAL OF MEDICAL ECONOMICS

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Single Domain Antibodies Are Potent Inhibitors of Low Density Lipoprotein Receptor Degradation

(2016) Elodie Weider et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

PCSK9 Inhibition With Monoclonal Antibodies: Modern Management of Hypercholesterolemia

(2016) Matthew K. Ito et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Amyloid Precursor-like Protein 2 and Sortilin Do Not Regulate the PCSK9 Convertase-mediated Low Density Lipoprotein Receptor Degradation but Interact with Each Other

(2015) Chutikarn Butkinaree et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Nanobodies: Natural Single-Domain Antibodies

(2013) Serge Muyldermans   Annual Review of Biochemistry

Anti-Rotavirus Protein Reduces Stool Output in Infants With Diarrhea: A Randomized Placebo-Controlled Trial

(2013) Shafiqul A. Sarker et al.   GASTROENTEROLOGY

An Antibody against the C-Terminal Domain of PCSK9 Lowers LDL Cholesterol Levels In Vivo

(2013) Felix Schiele et al.   JOURNAL OF MOLECULAR BIOLOGY

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Can Mediate Degradation of the Low Density Lipoprotein Receptor-Related Protein 1 (LRP-1)

(2013) Maryssa Canuel et al.   PLoS One

Novel Antiplatelet Agents: ALX-0081, a Nanobody Directed towards von Willebrand Factor

(2013) Jozef Bartunek et al.   Journal of Cardiovascular Translational Research

The biology and therapeutic targeting of the proprotein convertases

(2012) Nabil G. Seidah et al.   NATURE REVIEWS DRUG DISCOVERY

Circulating Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Regulates VLDLR Protein and Triglyceride Accumulation in Visceral Adipose Tissue

(2011) Anna Roubtsova et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH

(2011) Paola Lo Surdo et al.   EMBO REPORTS

Clinical impact of serum proteins on drug delivery

(2011) Felix Kratz et al.   JOURNAL OF CONTROLLED RELEASE

Increased Secretion of Lipoproteins in Transgenic Mice Expressing Human D374Y PCSK9 Under Physiological Genetic Control

(2010) Bronwen Herbert et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

A Proprotein Convertase Subtilisin-like/Kexin Type 9 (PCSK9) C-terminal Domain Antibody Antigen-binding Fragment Inhibits PCSK9 Internalization and Restores Low Density Lipoprotein Uptake

(2010) Yan G. Ni et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

In VivoEvidence That Furin from Hepatocytes Inactivates PCSK9

(2010) Rachid Essalmani et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials

(2010)   LANCET

Proprotein Convertase Subtilisin Kexin Type 9 Null Mice Are Protected From Postprandial Triglyceridemia

(2009) Cédric Le May et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

PCSK9 is expressed in pancreatic δ-cells and does not alter insulin secretion

(2009) Cédric Langhi et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

PCSK9 impedes hepatitis C virus infectionin vitroand modulates liver CD81 expression

(2009) Patrick Labonté et al.   HEPATOLOGY

A new method for measurement of total plasma PCSK9: clinical applications

(2009) Geneviève Dubuc et al.   JOURNAL OF LIPID RESEARCH

A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates

(2009) J. C. Y. Chan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide

(2008) LiXin Shan et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Proprotein convertase subtilisin/kexin type 9 (PCSK9): Hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration

(2008) Ahmed Zaid et al.   HEPATOLOGY

Regulation of ApoB Secretion by the Low Density Lipoprotein Receptor Requires Exit from the Endoplasmic Reticulum and Interaction with ApoE or ApoB

(2008) Daniel A. Blasiole et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Structural and Biochemical Characterization of the Wild Type PCSK9-EGF(AB) Complex and Natural Familial Hypercholesterolemia Mutants

(2008) Matthew J. Bottomley et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Function and distribution of circulating human PCSK9 expressed extrahepatically in transgenic mice

(2008) Yi Luo et al.   JOURNAL OF LIPID RESEARCH

Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor

(2008) D.-W. Zhang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA